Synthesis and antiproliferative activity of some new fluorinated Schiff bases derived from 1,2,4-triazoles
摘要:
In the present study, 2,6-diflurobenzohydrazide 1 and 4-fluorophenylisothiocyanate were used as the starting materials to synthesize 5-(2,6-diflurophenyl)-N-3-(4-fluorophenyl)-4H-1,2,4-triazole-3,4-diamine 3. Further, compound 3 reacted with fluoro substituted benzaldehydes to yield a series of Schiff bases 4(a-j). All the title compounds were characterized using IR, H-1 NMR, C-13 NMR, MS and elemental analyses. New compounds were evaluated for their antiproliferative effect using the MTT assay method against four human cancer cell lines (K562, COLO-205, MDA-MB231 and IMR-32) for the time period of 24 h. Among the series, compounds 4f, 4g and 4h showed good activity on all cell lines except K562, whereas the other compounds in the series exhibited moderate activity. Compound 4g could be a potential anticancer agent and therefore deserves further research. (C) 2013 Elsevier B.V. All rights reserved.
N‐phthalimidyl, benzamidyl, acetamidyl, carbamoyl, and ureayl derivatives of dihydropyridines and the application of these reagents as precursors for N‐centered radicals are presented. These aminated dihydropyridines could be used in radical‐transferhydroamination reactions of various electron‐rich as well as nonactivated olefins in the presence of thiols as polarity‐reversal catalysts. These reactions
[EN] AMINO-QUINOXALINE AND AMINO-QUINOLINE COMPOUNDS FOR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS<br/>[FR] AMINO-QUINOXALINE ET COMPOSÉS AMINO-QUINOLINE À UTILISER EN TANT QU'ANTAGONISTES DU RÉCEPTEUR A2a
申请人:SCHERING CORP
公开号:WO2009111442A1
公开(公告)日:2009-09-11
Compounds of the Formula (I), where W represents CH or N; and Q represents -CN, -C(=NOH)NH2, -CONHR1 or various herein described heterocyclic radicals; as well as pharmaceutically acceptable salts, solvates, esters and prodrugs thereof are adenosine A2a receptor antagonists and, therefore, are useful in the treatment of central nervous system diseases, in particular Parkinson's disease.
Triazolo-pyridazine derivatives as ligands for GABA receptors
申请人:Merck & Co., Inc.
公开号:US20030158203A1
公开(公告)日:2003-08-21
A class of substituted 1,2,4-triazolo[4,3-b]pyridazine derivatives, possessing a difluoro- or trifluoro-substituted phenyl ring at the 3-position, a triazolyl-methoxy moiety at the 6-position, and a tert-butyl group at the 7-position, are selective ligands for GABA
A
receptors, in particular having high affinity for &agr;2 and/or &agr;3 subunit thereof, and are accordingly of benefit in the treatment and/or prevention of disorders of the central nervous system, including anxiety and convulsions.
Pyrazolo-triazine derivatives as ligands for GABA receptors
申请人:Merck Sharp & Dohme Ltd.
公开号:US06476030B1
公开(公告)日:2002-11-05
Compounds according to Formula (I):
or a salt or prodrug thereof, have good affinity as ligands for the alpha2 and/or alpha3 subunit of the human GABAA receptor and are useful for treatment of disorders of the central nervous system, including anxiety and convulsions.
Triazolo-pyridazine derivatives as ligands for gaba receptors
申请人:Merck Sharp & Dohme Ltd.
公开号:US06500828B1
公开(公告)日:2002-12-31
1,2,4-triazolo[4,3-b]pyridazine derivatives, possessing a difluoro-or tri-fluoro-substituted phenyl ring at the 3-position, a triazolyl moiety at the 6-position, and a tert-butyl group at the 7-position, are selective ligands for GABAA receptors, in particular having high affinity for the &agr;2 and/or &agr;3 subunit thereof, and are useful in the treatment of anxiety and convulsions.